Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria.
Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria.
复制标题
DOI:
10.18632/oncotarget.14948
复制
发表时间:
2017-02-28
期刊:
影响因子:
--
通讯作者:
Barderas MG
中科院分区:
文献类型:
--
作者:
de la Cuesta F;Baldan-Martin M;Moreno-Luna R;Alvarez-Llamas G;Gonzalez-Calero L;Mourino-Alvarez L;Sastre-Oliva T;López JA;Vázquez J;Ruiz-Hurtado G;Segura J;Vivanco F;Ruilope LM;Barderas MG
Despite of the great advances in anti-hypertensive therapies, many patients under Renin-Angiotensin- System (RAS) suppression develop albuminuria, which is a clear indicator of therapeutic inefficiency. Hence, indicators of vascular function are needed to assess patients’ condition and help deciding future therapies. Proteomic analysis of circulating extracellular vesicles (EVs) showed two proteins, kalirin and chromodomain-helicase-DNA-binding protein 7 (CHD7), increased in albuminuric patients. A positive correlation of both with the expression of the endothelial activation marker E-selectin was found in EVs. In vitro analysis using TNFα-treated adult human endothelial cells proved their involvement in endothelial cell activation. Hence, we propose protein levels of kalirin and CHD7 in circulating EVs as novel endothelial dysfunction markers to monitor vascular condition in hypertensive patients with albuminuria.